Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
clinical trials
4
×
life sciences
national blog main
san diego blog main
san diego top stories
4
×
boston blog main
boston top stories
fda
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abeona therapeutics
accent therapeutics
achilles therapeutics
akcea therapeutics
akouos
alder biopharmaceuticals
alexion pharmaceuticals
alopecia areata
amarin
What
patients
4
×
fda
drug
market
medicine
time
add
advantages
ago
alnylam
approve
awaits
bar
bio
biological
brings
called
cancer
carbidopa
combination
control
crossed
daily
decades
decision
discovered
disease
eisai
expect
experience
fingers
flags
friday
gamble
gets
higher
historic
incidence
levodopa
lorcaserin
Language
unset
Current search:
biotech
×
patients
×
" san diego top stories "
×
" clinical trials "
×
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision